Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes

Soo I. Kim, Duckhyang Shin, Hyeon Lee, Byung-Yoon Ahn, Yeup Yoon, Meehyein Kim

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background/Aims: Hepatitis C virus (HCV) is one of the major human hepatic RNA viruses. Recently, we developed a liver-specific siRNA delivery technology using DTC-Apo composed of cationic liposomes (DTC) and apolipoprotein A-I (apo A-I). Here, we investigated whether DTC-Apo nanoparticles can systemically deliver siRNA into mouse hepatocytes expressing HCV proteins and inhibit their expression efficiently. Methods: A transient HCV model was constructed by hydrodynamic injection of plasmid DNA expressing viral structural proteins under hepatic control region and alpha1-antitrypsin promoter elements. Using this model, DTC-Apo containing HCV-core-specific siRNA was intravenously injected to assess antiviral activity as well as the duration of silencing. Results: Post-administration of DTC-Apo/HCV-specific siRNA at a dose of 2 mg siRNA/kg inhibited viral gene expression by 65-75% in the liver on day 2. Improved activity (95% knockdown on day 2) without immunotoxicity was obtained by 2′-OMe-modification at two U sequences on its sense strand. Notably, the gene silencing effect of the modified siRNA was still maintained at day 6, while the unmodified one lost RNAi activity after day 4. Conclusions: Our results suggest that DTC-Apo liposome is a highly potential delivery vehicle to transfer therapeutic siRNA especially targeting HCV to the liver.

Original languageEnglish
Pages (from-to)479-488
Number of pages10
JournalJournal of Hepatology
Volume50
Issue number3
DOIs
Publication statusPublished - 2009 Mar 1

Fingerprint

Apolipoprotein A-I
Liposomes
Hepacivirus
Small Interfering RNA
Liver
Apolipoproteins C
Viral Structural Proteins
Viral Genes
RNA Viruses
Gene Silencing
Hydrodynamics
RNA Interference
Nanoparticles
Antiviral Agents
Hepatocytes
Plasmids
Technology
Gene Expression
Injections
DNA

Keywords

  • Apolipoprotein A-I
  • Hepatitis C virus
  • siRNA
  • SR-BI
  • Systemic delivery
  • Tissue microarray

ASJC Scopus subject areas

  • Hepatology

Cite this

Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. / Kim, Soo I.; Shin, Duckhyang; Lee, Hyeon; Ahn, Byung-Yoon; Yoon, Yeup; Kim, Meehyein.

In: Journal of Hepatology, Vol. 50, No. 3, 01.03.2009, p. 479-488.

Research output: Contribution to journalArticle

Kim, Soo I. ; Shin, Duckhyang ; Lee, Hyeon ; Ahn, Byung-Yoon ; Yoon, Yeup ; Kim, Meehyein. / Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. In: Journal of Hepatology. 2009 ; Vol. 50, No. 3. pp. 479-488.
@article{50d595d342fd458f9824ff5f20887ec0,
title = "Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes",
abstract = "Background/Aims: Hepatitis C virus (HCV) is one of the major human hepatic RNA viruses. Recently, we developed a liver-specific siRNA delivery technology using DTC-Apo composed of cationic liposomes (DTC) and apolipoprotein A-I (apo A-I). Here, we investigated whether DTC-Apo nanoparticles can systemically deliver siRNA into mouse hepatocytes expressing HCV proteins and inhibit their expression efficiently. Methods: A transient HCV model was constructed by hydrodynamic injection of plasmid DNA expressing viral structural proteins under hepatic control region and alpha1-antitrypsin promoter elements. Using this model, DTC-Apo containing HCV-core-specific siRNA was intravenously injected to assess antiviral activity as well as the duration of silencing. Results: Post-administration of DTC-Apo/HCV-specific siRNA at a dose of 2 mg siRNA/kg inhibited viral gene expression by 65-75{\%} in the liver on day 2. Improved activity (95{\%} knockdown on day 2) without immunotoxicity was obtained by 2′-OMe-modification at two U sequences on its sense strand. Notably, the gene silencing effect of the modified siRNA was still maintained at day 6, while the unmodified one lost RNAi activity after day 4. Conclusions: Our results suggest that DTC-Apo liposome is a highly potential delivery vehicle to transfer therapeutic siRNA especially targeting HCV to the liver.",
keywords = "Apolipoprotein A-I, Hepatitis C virus, siRNA, SR-BI, Systemic delivery, Tissue microarray",
author = "Kim, {Soo I.} and Duckhyang Shin and Hyeon Lee and Byung-Yoon Ahn and Yeup Yoon and Meehyein Kim",
year = "2009",
month = "3",
day = "1",
doi = "10.1016/j.jhep.2008.10.029",
language = "English",
volume = "50",
pages = "479--488",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes

AU - Kim, Soo I.

AU - Shin, Duckhyang

AU - Lee, Hyeon

AU - Ahn, Byung-Yoon

AU - Yoon, Yeup

AU - Kim, Meehyein

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Background/Aims: Hepatitis C virus (HCV) is one of the major human hepatic RNA viruses. Recently, we developed a liver-specific siRNA delivery technology using DTC-Apo composed of cationic liposomes (DTC) and apolipoprotein A-I (apo A-I). Here, we investigated whether DTC-Apo nanoparticles can systemically deliver siRNA into mouse hepatocytes expressing HCV proteins and inhibit their expression efficiently. Methods: A transient HCV model was constructed by hydrodynamic injection of plasmid DNA expressing viral structural proteins under hepatic control region and alpha1-antitrypsin promoter elements. Using this model, DTC-Apo containing HCV-core-specific siRNA was intravenously injected to assess antiviral activity as well as the duration of silencing. Results: Post-administration of DTC-Apo/HCV-specific siRNA at a dose of 2 mg siRNA/kg inhibited viral gene expression by 65-75% in the liver on day 2. Improved activity (95% knockdown on day 2) without immunotoxicity was obtained by 2′-OMe-modification at two U sequences on its sense strand. Notably, the gene silencing effect of the modified siRNA was still maintained at day 6, while the unmodified one lost RNAi activity after day 4. Conclusions: Our results suggest that DTC-Apo liposome is a highly potential delivery vehicle to transfer therapeutic siRNA especially targeting HCV to the liver.

AB - Background/Aims: Hepatitis C virus (HCV) is one of the major human hepatic RNA viruses. Recently, we developed a liver-specific siRNA delivery technology using DTC-Apo composed of cationic liposomes (DTC) and apolipoprotein A-I (apo A-I). Here, we investigated whether DTC-Apo nanoparticles can systemically deliver siRNA into mouse hepatocytes expressing HCV proteins and inhibit their expression efficiently. Methods: A transient HCV model was constructed by hydrodynamic injection of plasmid DNA expressing viral structural proteins under hepatic control region and alpha1-antitrypsin promoter elements. Using this model, DTC-Apo containing HCV-core-specific siRNA was intravenously injected to assess antiviral activity as well as the duration of silencing. Results: Post-administration of DTC-Apo/HCV-specific siRNA at a dose of 2 mg siRNA/kg inhibited viral gene expression by 65-75% in the liver on day 2. Improved activity (95% knockdown on day 2) without immunotoxicity was obtained by 2′-OMe-modification at two U sequences on its sense strand. Notably, the gene silencing effect of the modified siRNA was still maintained at day 6, while the unmodified one lost RNAi activity after day 4. Conclusions: Our results suggest that DTC-Apo liposome is a highly potential delivery vehicle to transfer therapeutic siRNA especially targeting HCV to the liver.

KW - Apolipoprotein A-I

KW - Hepatitis C virus

KW - siRNA

KW - SR-BI

KW - Systemic delivery

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=59349118475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59349118475&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2008.10.029

DO - 10.1016/j.jhep.2008.10.029

M3 - Article

C2 - 19155084

AN - SCOPUS:59349118475

VL - 50

SP - 479

EP - 488

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 3

ER -